N-{(2Z)-4-[4-(3-chlorophenyl)piperazin-1-yl]but-2-enyl}-1,8-naphthalimide

Teresa Kowalska; Piotr Kowalski

doi:10.3390/M430

and

Institute of Organic Chemistry and Technology, Cracow University of Technology, 24 Warszawska Str., 31-155 Kraków, Poland

^*

Author to whom correspondence should be addressed.

Molbank2005, 2005(3), M430;https://doi.org/10.3390/M430

Version Notes

Order Reprints

Keywords:

arylpiperazines; serotonin receptors ligands

In continuation of our interest on synthesis and properties of arylpiperazine derivatives investigated as a serotonin receptors ligands [,,], herein we presented one-pot synthesis of N-{(2Z)-4-[4-(3-chlorophenyl)piperazin-1-yl]but-2-enyl}-1,8-naphthalimide (4). Starting materials e.g. 1,8-naphthalimide (1), (Z)-1,4-dichloro-2-butene (2), and 1-(3-chlorophenyl)piperazine hydrochloride (3) were commercially available reagents.

A mixture of the 1,8-naphthalimide (1) (3.94 g, 0.02 mole), powdered K₂CO₃ (4.14 g, 0.03 mole), catalytic amount of KI, and 40 mL of DMF was stirred at ambient temperature for 2 h. Than the (Z)-1,4-dichloro-2-butene (2) (2.50 g, 0.02 mole) was added and the stirring continued for another 10 h. Next, a new portion of anhydrous K₂CO₃ (5.25 g, 0.04 mole) and 1-(3-chlorophenyl)piperazine hydrochloride (3) (4.66 g, 0.02 mole) was added and the reaction mixture was stirred again for 10 h. The mixture was filtrated and the filtrate evaporated. The residue was suspended in 50 mL of acetone, which was decanted from semisolids, and the procedure repeated to give solid crystals. This material purified by crystallization with 1-butanol afforded of the desired N-{(2Z)-4-[4-(3-chlorophenyl)piperazin-1-yl]but-2-enyl}-1,8-naphthalimide (4) (3.1 g, 35%) as the light yellow crystals. For biological experiments the base 4 was converted into hydrochloride salt with ethanol saturated with HCl.

Melting point: 138–140 °C. (for HCl salt mp 279–281 °C)

¹H-NMR (80 MHz, CDCl₃): δ= 2.64–2.76 (m, 4H, 2CH₂-pip); 3.17–3.30 (m, 4H, 2CH₂-pip); 3.39 (d, 2H, CH₂-N-pip); 4.87 (d, 2H, CH₂-N-imide); 5.68–5.79 (m, 2H, CH=CH); 6.74–7.26 (m, 4H, ArH); 7.74 (t, 2H, H_3,6-imide); 8.22 (d, 2H, H_4,5-imide); 8.61(d, 2H, H_2,7-imide).

IR (KBr, cm^-1): 2954-2780 (CH); 1699, 1663 (C=O); 1590-1435 (C=C).

MS (EI, 70 eV; m/z, rel.%): 445 [M⁺] (21); 250 (61); 235 (100); 196 (15); 180 (32).

Elemental Analysis: Calculated for C₂₆H₂₄ClN₃O₂.HCl (482.41): C, 64.73%; H, 5.22%; N, 8.71%. Found: C, 64.79%; H, 5.33%; N, 8.48%.

Supplementary materials

Supplementary File 1Supplementary File 2Supplementary File 3

References

Kowalski, P.; Mokrosz, M. J.; Majka, Z.; Kowalska, T.; Duszyńska, B. J. Heterocyclic Chem. 2000, 37, 187–189.
Kowalski, P.; Kowalska, T.; Mokrosz, M.J.; Bojarski, A.J.; Charakchieva-Minol, S. Molecules 2001, 6, 784–795.
Bojarski, A.J.; Kowalski, P.; Kowalska, T.; Duszyńska, B.; Charakchieva-Minol, S.; Tatarczyńska, E.; Kłodzińska, A.; Chojnacka-Wójcik, E. Bioorg. Med. Chem. 2002, 10, 3817–3827. [PubMed]

Sample Availability: Available from MDPI.

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.